par Berghmans, Thierry 
Référence Revue des Maladies Respiratoires Actualites, 6, 4, page (459-469)
Publication Publié, 2014-09
Référence Revue des Maladies Respiratoires Actualites, 6, 4, page (459-469)
Publication Publié, 2014-09
Article révisé par les pairs
| Résumé : | During the last decade, molecular biology has considerably progressed allowing a better knowledge of molecular abnormalities inside non-small cell lung carcinoma (NSCLC). Among them, oncogenic driver mutations have been targeted and are currently under investigation. Extremely powerful drugs, tyrosine kinase inhibitors, are developed and revolutionised the therapeutic decision in NSCLC harbouring activating EGF-R mutation or ALK gene rearrangement. Other drugs are in development concerning signalisation pathways involving ROS-1, K-RAS, BRAF, HER-2 and many others. Immunotherapy also regains interest aiming at controlling immune checkpoints (CTLA4, PD1, PDL1) by means. of specific antibodies. These promising developments are justifying a new approach of the patient during the diagnostic phase (search for particular molecular abnormalities) and at the time of therapeutic decision, progressing from unselected chemotherapy to a personalised treatment. |
